---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-000928"
form_type: "8-K"
ticker: "CHRN"
cik: "0001549084"
company_name: "EKSO BIONICS HOLDINGS, INC."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:16:16.784764+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# Ekso Bionics expects record Q4 2024 revenue of $5.0-$5.1M, preliminary

## Summary
- Q4 2024 revenue estimated at $5.0-5.1M (company record vs $4.8M in Q4 2023).
- Cash $6.5M at Dec 31, 2024, down from $8.6M a year earlier.
- Net cash used in ops Q4 2024 estimated $1.5M, improving from $1.6M year ago.
- CEO highlights initial CMS reimbursement for Ekso Indego Personal device.
- Full Q4 and FY 2024 results expected in first week of March 2025.

## SEC filing metadata
- accession: 0001437749-25-000928
- form_type: 8-K
- ticker: CHRN
- cik: 0001549084
- company_name: EKSO BIONICS HOLDINGS, INC.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549084/000143774925000928/0001437749-25-000928-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549084/000143774925000928/ekso20250108_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-000928
- JSON: https://secwatch.observer/filing/0001437749-25-000928.json
- Plain text: https://secwatch.observer/filing/0001437749-25-000928.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.